Proactive Investors - Run By Investors For Investors

CytoDyn to meet with FDA to finalize next steps on leronlimab drug trial for HIV

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors the FDA has requested an in-person meeting to discuss and potentially finalize the biotechnology company’s protocol for a trial of flagship drug leronlimab as a single treatment for HIV patients.

Dr Pourhassan also addresses the company's stagnant share price, and whether this poses a risk.

 
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full CYDY profile View Profile

CytoDyn Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use